3.09
-0.005(-0.16%)
Currency In USD
| Previous Close | 3.09 |
| Open | 3.06 |
| Day High | 3.13 |
| Day Low | 3.03 |
| 52-Week High | 4.02 |
| 52-Week Low | 2.46 |
| Volume | 394,027 |
| Average Volume | 387,182 |
| Market Cap | 241.02M |
| PE | -1.74 |
| EPS | -1.77 |
| Moving Average 50 Days | 3.11 |
| Moving Average 200 Days | 3.17 |
| Change | -0.01 |
If you invested $1000 in Atea Pharmaceuticals, Inc. (AVIR) since IPO date, it would be worth $101.68 as of December 04, 2025 at a share price of $3.085. Whereas If you bought $1000 worth of Atea Pharmaceuticals, Inc. (AVIR) shares 3 years ago, it would be worth $660.6 as of December 04, 2025 at a share price of $3.085.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 19, 2025 12:00 PM GMT
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 07, 2025 1:00 PM GMT
Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ETBOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
GlobeNewswire Inc.
Nov 05, 2025 12:00 PM GMT
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to